nucynta er Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nucynta Er, and what generic alternatives are available?
Nucynta Er is a drug marketed by Collegium Pharm Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and seventy-two patent family members in thirty-one countries.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tapentadol hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Nucynta Er
Nucynta Er was eligible for patent challenges on November 20, 2012.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 27, 2025. This may change due to patent challenges or generic licensing.
There have been nineteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
There are three tentative approvals for the generic drug (tapentadol hydrochloride), which indicates the potential for near-term generic launch.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for nucynta er?
- What are the global sales for nucynta er?
- What is Average Wholesale Price for nucynta er?
Summary for nucynta er
International Patents: | 272 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 6 |
Patent Applications: | 344 |
Drug Prices: | Drug price information for nucynta er |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for nucynta er |
DailyMed Link: | nucynta er at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for nucynta er
Generic Entry Date for nucynta er*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for nucynta er
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
GrĂ¼nenthal GmbH | Phase 4 |
Ortho-McNeil Janssen Scientific Affairs, LLC | Phase 3 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
Pharmacology for nucynta er
Drug Class | Opioid Agonist |
Mechanism of Action | Opioid Agonists |
Paragraph IV (Patent) Challenges for NUCYNTA ER
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
NUCYNTA ER | Extended-release Tablets | tapentadol hydrochloride | 50 mg, 100 mg, 150 mg, 200 mg, and 250 mg | 200533 | 2 | 2012-11-20 |
US Patents and Regulatory Information for nucynta er
nucynta er is protected by four US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of nucynta er is ⤷ Subscribe.
This potential generic entry date is based on patent 7,994,364.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-001 | Aug 25, 2011 | RX | Yes | No | 8,114,383 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-005 | Aug 25, 2011 | RX | Yes | Yes | 7,994,364*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-002 | Aug 25, 2011 | RX | Yes | No | 8,536,130*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-001 | Aug 25, 2011 | RX | Yes | No | 11,344,512*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for nucynta er
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-003 | Aug 25, 2011 | 6,071,970 | ⤷ Subscribe |
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-002 | Aug 25, 2011 | 8,420,056 | ⤷ Subscribe |
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-003 | Aug 25, 2011 | 8,309,060 | ⤷ Subscribe |
Collegium Pharm Inc | NUCYNTA ER | tapentadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200533-001 | Aug 25, 2011 | RE39593 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for nucynta er
See the table below for patents covering nucynta er around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 102004032051 | Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform | ⤷ Subscribe |
Norway | 20041924 | ⤷ Subscribe | |
Slovenia | 1799633 | ⤷ Subscribe | |
Croatia | P20170746 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for nucynta er
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1439829 | C20110003 00036 | Estonia | ⤷ Subscribe | PRODUCT NAME: PALEXIA; REG NO/DATE: RR-4/42 22.10.2010 |
0693475 | 2011/010 | Ireland | ⤷ Subscribe | PRODUCT NAME: TAPENTADOL IN BASIC FORM OR IN THE FORM OF A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY TAPENTADOL HYDROCHLORIDE; NAT REGISTRATION NO/DATE: PA1189/007/001-008 20101221; FIRST REGISTRATION NO/DATE: PA1189/008/001-008 21/12/2010 GERMANY 75043.00.00 75044.00.00 75045.00.00 19/08/2010 GERMANY 76261.00.00 76262.00.00 76263.00.00 76264.00.00 76265.00.00 19/08/2010 GERMANY 75046.00.00 75047.00.00 75048.00.00 19/08/2010 GERMANY 76266.00.00 76267.00.00 76268.00.0076269.00.00 76270.00.00 20100819 |
0693475 | SPC/GB11/031 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: TAPENTADOL IN THE FORM OF ITS BASE OR A SALT OF A PHYSIOLOGICALLY COMPATIBLE ACID, ESPECIALLY THE HYDROCHLORIDE SALT.; REGISTERED: DE 75043 20100819; UK PL 21727/0032 - 0050 20110204 |
0693475 | PA2011007,C0693475 | Lithuania | ⤷ Subscribe | PRODUCT NAME: TAPENTADOLUM; NAT. REGISTRATION NO/DATE: LT/1/10/2341/001 - LT/1/10/2341/66, 2011 02 19; LT/1/10/2342/001 - LT/1/10/2342/110 20110219; FIRST REGISTRATION: 75043.00.00 - 75048.00.00, 2010 08 19; 76261.00.00 - 76270.00.00 20100819 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Nucynta er Market Analysis and Financial Projection Experimental
More… ↓